ESTRO 2025 - Abstract Book

S132

Invited Speaker

ESTRO 2025

4870

Speaker Abstracts Veterinary radiotherapy: The why, when, and how? Crystal Sulaiman Radiation Oncology, University Hospital of Zurich (USZ), Zurich, Switzerland. Radiation Oncology, University Animal Hospital Zurich (UZH), Zurich, Switzerland Abstract: Veterinary Radiotherapy is not widely known and considered perhaps more of a specialized field, likely due to its limited accessibility. This session invites those who have a passion for animals and who are curious to know how our radiotherapy skills may be transferred to their care. We will explore what a day in the small animal clinic entails, specifically the entire radiotherapy process, with an insight to its interdisciplinary facets. From indications and intent to treatment setup and delivery, the key differences and similarities of RT in the human vs. veterinary setting will be examined. As dogs and cats are a unique cohort of patients, we will highlight a few special considerations including lifespan, wishes and financial implications. This teaching will aim to provide answers to one frequently posed question: Why treat animals?

4871

Speaker Abstracts RT for IDH-wild-type glioma: Is something changing? Maximilian Niyazi Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

Abstract:

IDH-wt gliomas encompass a spectrum of aggressive tumors, with glioblastoma as the most common and lethal subtype. The integration of molecular markers into classification has refined diagnosis, distinguishing these tumors from IDH-mut gliomas and reinforcing their distinct biological behavior. Glioblastomas, whether diagnosed histologically or defined by molecular features, remain the primary challenge in this group, necessitating continuous refinement of treatment strategies. Radiotherapy remains a key component of therapy, with recent updates in the ESTRO-EANO guidelines redefining target volume margins based on recurrence pattern studies. These refinements aim to improve tumor control while minimizing unnecessary exposure to healthy brain tissue. Advancements in radiotherapy delivery, imaging integration, and novel combination strategies are reshaping the treatment landscape. High-precision techniques, adaptive planning, and dose escalation hold promise for improving outcomes. This presentation will discuss these developments and their potential to refine the SOC for IDH-wt gliomas.

4874

Speaker Abstracts Prostate single SBRT Ciro Franzese Department of Biochemical Science, Humanitas University, Milan, Italy. Department of Radiation Oncology, Humanitas Research Hospital IRCCS & San Pio X, Milan, Italy